It it’s also not cratering, which we’ve seen all too many times when bio’s have reported AD results.
We do need some sort of validation from either a partnership with a big pharma company who believes our results can get the drug approved, an irrefutable peer-reviewed article, or accelerated approval status from the FDA.
One would also think these results would warrant a session at this year’s CTAD event. I was thinking there would’ve been a conference call sometime today…